Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15840617 | 0.84 | GPR55 (0.66) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15840505 | 0.79 | GPR55 (0.65) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25132370 | 0.79 | ALDH1A1 (0.71) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15840638 | 0.77 | ALDH1A1 (0.68) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15840535 | 0.77 | GPR55 (0.67) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12470464 | 0.76 | ALDH1A1 (0.69) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15840555 | 0.75 | RAB9A (0.71) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15840506 | 0.74 | ALDH1A1 (0.64) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9771208 | 0.72 | ALDH1A1 (0.57) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15840671 | 0.72 | LMNA (0.68) | ALDH1A1LMNAMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | Errico, Joseph P. (US) | 2014-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179681-A1 | METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT | EGFR, ERBB2, ERBB3 | ALDH1A1 4348/4885LMNA 2183/4885MEN1 3121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.